Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...
Pearland school board members knew they couldn't personally vet hundreds of books for “indecent” or “profane” content prohibited under a new state law. So when they met this fall to consider a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback